H – 15 - Cancers
Predictors of cancer risk in the long-term solid-organ transplant
recipient
Sam N. Sherston, Robert P. Carroll, Paul N. Harden, and Kathryn J. Wood
Transplantation 2014; 97: 605-611
ABSTRACT
Malignancy is increasingly the leading cause of mortality in solid-organ recipients. Cancer
incidence among the transplant population is overall threefold to fivefold higher than the
general population with poorer outcomes for late-stage disease. Insights into the
identification of patients at particular risk of developing a posttransplantation malignancy are
imperative to ensure appropriate measures are instigated to reduce associated morbidity and
mortality. This review focuses on potential clinical, immunologic, and genetic translational
markers aimed at identifying
long-term solid-organ transplant patients at high risk of developing cancer.
Keywords: Cancer, Posttransplantation, Markers, Malignancy, Transplantation, Long-term.
COMMENTS
Transplantation is the treatment of choice for patients with end-stage organ failure.
Progressive advances in clinical management and immunosuppressive regimens have
resulted in a significant reduction in the number of acute rejection episodes and increased 1year graft survival rates in transplant recipients. However, despite these advances in shortterm outcomes after transplantation, there has been minimal change in long-term allograft
survival.
Pr. Jacques CHANARD
Professor of Nephrology